Premium
Hot Features
Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
ORLANDO, Fla., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Today’s featured company is a simple story. It’s a uranium play. For those of you who have dabbled in the markets for any length of time you may...
Company Announcement IND for HuMax(R)-TF-ADC submitted to FDA Genmab's first IND submission for antibody-drug conjugate (ADC) product Patient enrolment in clinical trial expected...
Company Announcement Genentech and Biogen Idec refused re-hearing in Arzerra patent infringement case COPENHAGEN, Denmark, July 15, 2013 (GLOBE NEWSWIRE) -- Genmab A/S (Copenhagen:GEN...
Company Announcement First Phase III study with subcutaneous formulation of ofatumumab Ofatumumab to be investigated in new autoimmune area - pemphigus vulgaris Patient...
Media Release Antibody-drug conjugate (ADC) to be developed for cancer Combines strength of HuMax(R)-TAC with next generation PBD-based warhead technology 50:50 partnership ...
Company Announcement Teprotumumab (RG1507) to be investigated for new indication River Vision Development Corporation to conduct clinical development under a license from Roche...
Company Announcement Genmab establishes Sponsored Level 1 ADR program Genmab ADRs can be traded on US over-the-counter (OTC) market effective today ADR ticker symbol GMXAY...
Company Announcement Median 22.4 month progression free survival in patients treated with ofatumumab plus chlorambucil, an improvement of 9.3 months compared to chlorambucil alone No...
Company Announcement Genentech and Biogen Idec have filed for re-hearing in the United States COPENHAGEN, Denmark, May 17, 2013 (GLOBE NEWSWIRE) -- Genmab A/S (Copenhagen:GEN) announced...
COPENHAGEN, Denmark, May 7, 2013 (GLOBE NEWSWIRE) -- Interim Report First Quarter 2013 Arzerra(r) received approval in Japan Arzerra net sales increased 65% over Q1...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.015 | -15 | 0.1 | 0.1 | 0.085 | 15120 | 0.09841272 | CS |
| 4 | -0.015 | -15 | 0.1 | 0.1 | 0.085 | 12790 | 0.09733586 | CS |
| 12 | -0.155 | -64.5833333333 | 0.24 | 0.24 | 0.085 | 37585 | 0.14505994 | CS |
| 26 | -0.225 | -72.5806451613 | 0.31 | 0.435 | 0.085 | 39643 | 0.23095126 | CS |
| 52 | -0.025 | -22.7272727273 | 0.11 | 0.435 | 0.075 | 33655 | 0.23039679 | CS |
| 156 | -0.015 | -15 | 0.1 | 0.435 | 0.045 | 17551 | 0.22520597 | CS |
| 260 | -0.015 | -15 | 0.1 | 0.435 | 0.045 | 17551 | 0.22520597 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
